September 30, 2004 -- Cortical’s board of management has welcomed Dr Su-Peing Ng who joined the company as CEO on 19 August 2004.
Dr Ng joins Cortical having recently returned from the UK where she was Business Development Director for Chiron Vaccines responsible for the company’s US$300m influenza franchise.
Cortical’s core strengths are medicinal chemistry, applied biology and virtual drug development. Dr Ng brings to the company several years of international pharmaceutical and biotechnology business and commercial strategy development experience.
Dr Ng is a qualified medical practitioner and holds an MBA from the Melbourne Business School where she graduated with distinction. As part of her MBA program, Dr Ng studied at the Fuqua Business School at Duke University.
Dr Ng’s mission for Cortical is to expand the pipeline beyond the current focus of macrophage migratory inhibitory factor (MIF) to include other molecules with potential anti-inflammatory effects.
In early October (6th – 7th), Dr Ng will participate in an Australian Biotechnology Mission to the Medicon Valley conference at Bella Center in Copenhagen.
“As a niche Australian biotechnology company, the mission provides an ideal opportunity to showcase our research and development activities and to meet other prospective research and commercialisation partners. I am very pleased to be part of this initiative,” said Dr Ng.
About Cortical Pty Ltd
Cortical is a Melbourne based discovery research and development company, which was founded in 2003 by Associate Professor Eric Morand and Dr Magdy Iskander of Monash University. Cortical’s mission is to produce smallmolecule solutions to therapeutic targets in inflammation, and to commercialise these via strategic partnerships with pharmaceutical and biotechnology companies.
Therapeutics developed by Cortical’s R&D team will be targeted at diseases characterised by inflammation such as arthritis, psoriasis, asthma, multiple sclerosis and colitis.
Cortical’s former CEO, Dr Errol Malta, will continue as Drug Development Advisor to the company and will join Cortical’s Research and Development Advisory Board.
